Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.
Product Name : GLS-010
Product Type : Antibody
Upfront Cash : Inapplicable
June 09, 2023
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
Product Name : GLS-010
Product Type : Antibody
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
